

V. Anhang

V.1. Referenzen

1. Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, Sieper J. 1998. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. *Arthritis Rheum* 41: 58-67
2. Brandt J, Bollow M, Haberle J, Rudwaleit M, Eggens U, Distler A, Sieper J, Braun J. 1999. Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: many, but not all patients with sacroiliitis have spondyloarthropathy. *Rheumatology (Oxford)* 38: 831-6
3. Reveille JD, Arnett FC. 2005. Spondyloarthritis: update on pathogenesis and management. *Am J Med* 118: 592-603
4. Carter N, Williamson L, Kennedy LG, Brown MA, Wordsworth BP. 2000. Susceptibility to ankylosing spondylitis. *Rheumatology (Oxford)* 39: 445
5. van der Linden SM, Cats A, Valkenburg HA. 1988. On the prevalence of ankylosing spondylitis. *J Rheumatol* 15: 375-7
6. Lopez-Larrea C, Sujirachato K, Mehra NK, Chiewsilp P, Isarangkura D, Kanga U, Dominguez O, Coto E, Pena M, Setien F, et al. 1995. HLA-B27 subtypes in Asian patients with ankylosing spondylitis. Evidence for new associations. *Tissue Antigens* 45: 169-76
7. Ren EC, Koh WH, Sim D, Boey ML, Wee GB, Chan SH. 1997. Possible protective role of HLA-B*2706 for ankylosing spondylitis. *Tissue Antigens* 49: 67-9
8. D'Amato M, Fiorillo MT, Galeazzi M, Martinetti M, Amoroso A, Sorrentino R. 1995. Frequency of the new HLA-B*2709 allele in ankylosing spondylitis patients and healthy individuals. *Dis Markers* 12: 215-7
9. Hammer RE, Maika SD, Richardson JA, Tang JP, Taurog JD. 1990. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. *Cell* 63: 1099-112

10. Taurog JD, Maika SD, Simmons WA, Breban M, Hammer RE. 1993. Susceptibility to inflammatory disease in HLA-B27 transgenic rat lines correlates with the level of B27 expression. *J Immunol* 150: 4168-78
11. Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernandez-Sueiro JL, Balish E, Hammer RE. 1994. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. *J Exp Med* 180: 2359-64
12. Khare SD, Bull MJ, Hanson J, Luthra HS, David CS. 1998. Spontaneous inflammatory disease in HLA-B27 transgenic mice is independent of MHC class II molecules: a direct role for B27 heavy chains and not B27-derived peptides. *J Immunol* 160: 101-6
13. Peh CA, Burrows SR, Barnden M, Khanna R, Cresswell P, Moss DJ, McCluskey J. 1998. HLA-B27-restricted antigen presentation in the absence of tapasin reveals polymorphism in mechanisms of HLA class I peptide loading. *Immunity* 8: 531-42
14. Bowness P, Zaccai N, Bird L, Jones EY. 1999. HLA-B27 and disease pathogenesis: new structural and functional insights. *Expert Rev Mol Med* 1999: 1-10
15. Campbell RD, Trowsdale J. 1993. Map of the human MHC. *Immunol Today* 14: 349-52
16. Huizinga TW, Westendorp RG, Bollen EL, Keijsers V, Brinkman BM, Langermans JA, Breedveld FC, Verweij CL, van de Gaer L, Dams L, Crusius JB, Garcia-Gonzalez A, van Oosten BW, Polman CH, Pena AS. 1997. TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. *J Neuroimmunol* 72: 149-53
17. Martinez A, Fernandez-Arquero M, Balsa A, Rubio A, Alves H, Pascual-Salcedo D, Martin-Mola E, de la Concha EG. 2001. Primary association of a MICA allele with protection against rheumatoid arthritis. *Arthritis Rheum* 44: 1261-5
18. Bouma G, Crusius JB, Oudkerk Pool M, Kolkman JJ, von Blomberg BM, Kostense PJ, Giphart MJ, Schreuder GM, Meuwissen SG, Pena AS. 1996. Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. *Scand J Immunol* 43: 456-63

19. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. 1997. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. *Proc Natl Acad Sci U S A* 94: 3195-9
20. Kaijzel EL, Brinkman BM, van Krugten MV, Smith L, Huizinga TW, Verjans GM, Breedveld FC, Verweij CL. 1999. Polymorphism within the tumor necrosis factor alpha (TNF) promoter region in patients with ankylosing spondylitis. *Hum Immunol* 60: 140-4
21. Hohler T, Schaper T, Schneider PM, Meyer zum Buschenfelde KH, Marker-Hermann E. 1998. Association of different tumor necrosis factor alpha promoter allele frequencies with ankylosing spondylitis in HLA-B27 positive individuals. *Arthritis Rheum* 41: 1489-92
22. McGarry F, Walker R, Sturrock R, Field M. 1999. The -308.1 polymorphism in the promoter region of the tumor necrosis factor gene is associated with ankylosing spondylitis independent of HLA-B27. *J Rheumatol* 26: 1110-6
23. Martinez-Borra J, Gonzalez S, Lopez-Vazquez A, Gelaz MA, Armas JB, Kanga U, Mehra NK, Lopez-Larrea C. 2000. HLA-B27 alone rather than B27-related class I haplotypes contributes to ankylosing spondylitis susceptibility. *Hum Immunol* 61: 131-9
24. Braun J, Yin Z, Spiller I, Siegert S, Rudwaleit M, Liu L, Radbruch A, Sieper J. 1999. Low secretion of tumor necrosis factor alpha, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. *Arthritis Rheum* 42: 2039-44
25. Rudwaleit M, Siegert S, Yin Z, Eick J, Thiel A, Radbruch A, Sieper J, Braun J. 2001. Low T cell production of TNFalpha and IFNgamma in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. *Ann Rheum Dis* 60: 36-42
26. Abbas AKL, Andrew H.; Pober, Jordan S. 2000. *Cellular and Molecular Immunology*: Saunders
27. Linsley PS, Ledbetter JA. 1993. The role of the CD28 receptor during T cell responses to antigen. *Annu Rev Immunol* 11: 191-212
28. Smith KA. 1988. Interleukin-2: inception, impact, and implications. *Science* 240: 1169-76
29. Swain SL, Bradley LM, Croft M, Tonkonogy S, Atkins G, Weinberg AD, Duncan DD, Hedrick SM, Dutton RW, Huston G. 1991. Helper T-cell

- subsets: phenotype, function and the role of lymphokines in regulating their development. *Immunol Rev* 123: 115-44
30. Powers GD, Abbas AK, Miller RA. 1988. Frequencies of IL-2- and IL-4-secreting T cells in naive and antigen-stimulated lymphocyte populations. *J Immunol* 140: 3352-7
 31. Weinberg AD, English M, Swain SL. 1990. Distinct regulation of lymphokine production is found in fresh versus in vitro primed murine helper T cells. *J Immunol* 144: 1800-7
 32. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. 1986. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. *J Immunol* 136: 2348-57
 33. Mosmann TR, Coffman RL. 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. *Annu Rev Immunol* 7: 145-73
 34. Mosmann TR, Schumacher JH, Street NF, Budd R, O'Garra A, Fong TA, Bond MW, Moore KW, Sher A, Fiorentino DF. 1991. Diversity of cytokine synthesis and function of mouse CD4+ T cells. *Immunol Rev* 123: 209-29
 35. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM. 1993. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. *Science* 260: 547-9
 36. Seder RA, Gazzinelli R, Sher A, Paul WE. 1993. Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. *Proc Natl Acad Sci U S A* 90: 10188-92
 37. Le Gros G, Ben-Sasson SZ, Seder R, Finkelman FD, Paul WE. 1990. Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation of IL-4-producing cells. *J Exp Med* 172: 921-9
 38. Swain SL, Weinberg AD, English M, Huston G. 1990. IL-4 directs the development of Th2-like helper effectors. *J Immunol* 145: 3796-806
 39. Constant S, Pfeiffer C, Woodard A, Pasqualini T, Bottomly K. 1995. Extent of T cell receptor ligation can determine the functional differentiation of naive CD4+ T cells. *J Exp Med* 182: 1591-6
 40. Chang JC, Zhang L, Edgerton TL, Kaplan AM. 1990. Heterogeneity in direct cytotoxic function of L3T4 T cells. TH1 clones express higher

- cytotoxic activity to antigen-presenting cells than TH2 clones. *J Immunol* 145: 409-16
41. Rulifson IC, Sperling AI, Fields PE, Fitch FW, Bluestone JA. 1997. CD28 costimulation promotes the production of Th2 cytokines. *J Immunol* 158: 658-65
 42. Liblau RS, Singer SM, McDevitt HO. 1995. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. *Immunol Today* 16: 34-8
 43. Romagnani S. 1994. Lymphokine production by human T cells in disease states. *Annu Rev Immunol* 12: 227-57
 44. De Rosa SC, Herzenberg LA, Roederer M. 2001. 11-color, 13-parameter flow cytometry: identification of human naive T cells by phenotype, function, and T-cell receptor diversity. *Nat Med* 7: 245-8
 45. Plebanski M, Saunders M, Burtles SS, Crowe S, Hooper DC. 1992. Primary and secondary human in vitro T-cell responses to soluble antigens are mediated by subsets bearing different CD45 isoforms. *Immunology* 75: 86-91
 46. Akbar AN, Terry L, Timms A, Beverley PC, Janossy G. 1988. Loss of CD45R and gain of UCHL1 reactivity is a feature of primed T cells. *J Immunol* 140: 2171-8
 47. Clement LT. 1991. Functional and phenotypic properties of 'naive' and 'memory' CD4+ T cells in the human. *Immunol Res* 10: 189-95
 48. Morimoto C, Letvin NL, Boyd AW, Hagan M, Brown HM, Kornacki MM, Schlossman SF. 1985. The isolation and characterization of the human helper inducer T cell subset. *J Immunol* 134: 3762-9
 49. de Jong R, Brouwer M, Miedema F, van Lier RA. 1991. Human CD8+ T lymphocytes can be divided into CD45RA+ and CD45RO+ cells with different requirements for activation and differentiation. *J Immunol* 146: 2088-94
 50. Hamann D, Baars PA, Rep MH, Hooibrink B, Kerkhof-Garde SR, Klein MR, van Lier RA. 1997. Phenotypic and functional separation of memory and effector human CD8+ T cells. *J Exp Med* 186: 1407-18
 51. Utsuyama M, Hirokawa K, Kurashima C, Fukayama M, Inamatsu T, Suzuki K, Hashimoto W, Sato K. 1992. Differential age-change in the numbers of

- CD4+CD45RA+ and CD4+CD29+ T cell subsets in human peripheral blood. *Mech Ageing Dev* 63: 57-68
52. van Lier RA, Borst J, Vroom TM, Klein H, Van Mourik P, Zeijlemaker WP, Melief CJ. 1987. Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen. *J Immunol* 139: 1589-96
 53. Martorell J, Rojo I, Vilella R, Martinez-Caceres E, Vives J. 1990. CD27 induction on thymocytes. *J Immunol* 145: 1356-63
 54. Maurer D, Holter W, Majdic O, Fischer GF, Knapp W. 1990. CD27 expression by a distinct subpopulation of human B lymphocytes. *Eur J Immunol* 20: 2679-84
 55. Sugita K, Hirose T, Rothstein DM, Donahue C, Schlossman SF, Morimoto C. 1992. CD27, a member of the nerve growth factor receptor family, is preferentially expressed on CD45RA+ CD4 T cell clones and involved in distinct immunoregulatory functions. *J Immunol* 149: 3208-16
 56. Sugita K, Robertson MJ, Torimoto Y, Ritz J, Schlossman SF, Morimoto C. 1992. Participation of the CD27 antigen in the regulation of IL-2-activated human natural killer cells. *J Immunol* 149: 1199-203
 57. Camerini D, Walz G, Loenen WA, Borst J, Seed B. 1991. The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family. *J Immunol* 147: 3165-9
 58. Agematsu K, Kobata T, Sugita K, Hirose T, Schlossman SF, Morimoto C. 1995. Direct cellular communications between CD45R0 and CD45RA T cell subsets via CD27/CD70. *J Immunol* 154: 3627-35
 59. Croft M. 2003. Costimulation of T cells by OX40, 4-1BB, and CD27. *Cytokine Growth Factor Rev* 14: 265-73
 60. Hintzen RQ, Lens SM, Lammers K, Kuiper H, Beckmann MP, van Lier RA. 1995. Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation. *J Immunol* 154: 2612-23
 61. Yamada A, Salama AD, Sho M, Najafian N, Ito T, Forman JP, Kewalramani R, Sandner S, Harada H, Clarkson MR, Mandelbrot DA, Sharpe AH, Oshima H, Yagita H, Chalasani G, Lakkis FG, Auchincloss H, Jr., Sayegh MH. 2005. CD70 signaling is critical for CD28-independent CD8+ T cell-mediated alloimmune responses in vivo. *J Immunol* 174: 1357-64

62. Ochsenbein AF, Riddell SR, Brown M, Corey L, Baerlocher GM, Lansdorp PM, Greenberg PD. 2004. CD27 expression promotes long-term survival of functional effector-memory CD8⁺ cytotoxic T lymphocytes in HIV-infected patients. *J Exp Med* 200: 1407-17
63. Stonans I, Stonane E, Vogelsang H, Junker U, Jager L. 1996. Differential expression of cytokine genes in CD27-positive and -negative CD4 lymphocyte subsets from healthy humans and rheumatoid arthritis patients. *Rheumatol Int* 15: 249-54
64. Elson LH, Nutman TB, Metcalfe DD, Prussin C. 1995. Flow cytometric analysis for cytokine production identifies T helper 1, T helper 2, and T helper 0 cells within the human CD4⁺CD27⁻ lymphocyte subpopulation. *J Immunol* 154: 4294-301
65. Baars PA, Maurice MM, Rep M, Hooibrink B, van Lier RA. 1995. Heterogeneity of the circulating human CD4⁺ T cell population. Further evidence that the CD4⁺CD45RA⁻CD27⁻ T cell subset contains specialized primed T cells. *J Immunol* 154: 17-25
66. De Jong R, Brouwer M, Hooibrink B, Van der Pouw-Kraan T, Miedema F, Van Lier RA. 1992. The CD27⁻ subset of peripheral blood memory CD4⁺ lymphocytes contains functionally differentiated T lymphocytes that develop by persistent antigenic stimulation in vivo. *Eur J Immunol* 22: 993-9
67. Hintzen RQ, Fiszer U, Fredrikson S, Rep M, Polman CH, van Lier RA, Link H. 1995. Analysis of CD27 surface expression on T cell subsets in MS patients and control individuals. *J Neuroimmunol* 56: 99-105
68. Petersen LD, Duinkerken G, Bruining GJ, van Lier RA, de Vries RR, Roep BO. 1996. Increased numbers of in vivo activated T cells in patients with recent onset insulin-dependent diabetes mellitus. *J Autoimmun* 9: 731-7
69. Baars PA, Ribeiro Do Couto LM, Leusen JH, Hooibrink B, Kuijpers TW, Lens SM, van Lier RA. 2000. Cytolytic mechanisms and expression of activation-regulating receptors on effector-type CD8⁺CD45RA⁺CD27⁻ human T cells. *J Immunol* 165: 1910-7
70. Hamann D, Kostense S, Wolthers KC, Otto SA, Baars PA, Miedema F, van Lier RA. 1999. Evidence that human CD8⁺CD45RA⁺CD27⁻ cells are induced by antigen and evolve through extensive rounds of division. *Int Immunol* 11: 1027-33

71. van der Linden S, Valkenburg HA, Cats A. 1984. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. *Arthritis Rheum* 27: 361-8
72. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. 1994. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. *J Rheumatol* 21: 2286-91
73. Miltenyi S, Muller W, Weichel W, Radbruch A. 1990. High gradient magnetic cell separation with MACS. *Cytometry* 11: 231-8
74. Bishop YMM, Fienberg SE, Holland PW. 1975. *Discrete multivariate analysis: theory and practice*. Cambridge, Mass.: MIT Press. x, 557 p. pp.
75. Marker-Hermann E, Frauendorf E, Zeidler H, Sieper J. 2004. [Pathogenesis of ankylosing spondylitis-mechanisms of disease manifestation and chronicity]. *Z Rheumatol* 63: 187-92
76. Brown MA, Pile KD, Kennedy LG, Calin A, Darke C, Bell J, Wordsworth BP, Cornelis F. 1996. HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom. *Ann Rheum Dis* 55: 268-70
77. MacLean IL, Iqbal S, Woo P, Keat AC, Hughes RA, Kingsley GH, Knight SC. 1993. HLA-B27 subtypes in the spondarthropathies. *Clin Exp Immunol* 91: 214-9
78. Ringrose JH. 1999. HLA-B27 associated spondyloarthritis, an autoimmune disease based on crossreactivity between bacteria and HLA-B27? *Ann Rheum Dis* 58: 598-610
79. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, Golder W, Gromnica-Ihle E, Kellner H, Schneider M, Sorensen H, Zeidler H, Reddig J, Sieper J. 2003. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. *Arthritis Rheum* 48: 2224-33
80. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, Sorensen H, Zeidler H, Thriene W, Sieper J. 2002. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. *Lancet* 359: 1187-93
81. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, Eggens U, Distler A, Sieper J. 1995. Use of immunohistologic and in situ

hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. *Arthritis Rheum* 38: 499-505

82. Lohning M, Grogan JL, Coyle AJ, Yazdanbakhsh M, Meisel C, Gutierrez-Ramos JC, Radbruch A, Kamradt T. 1999. T1/ST2 expression is enhanced on CD4+ T cells from schistosome egg-induced granulomas: analysis of Th cell cytokine coexpression ex vivo. *J Immunol* 162: 3882-9